HCPCS code J0572: Buprenorphine/naloxone billing guide

Key takeaways

HCPCS code J0572 covers oral buprenorphine/naloxone products holding 3 mg or less buprenorphine per unit, and it has been active since January 1, 2015

The tier comes from total milligrams dispensed, so match the dose to one code and bill a single unit of it

J0571 through J0575 form the oral dosage ladder, while J0570 is a fixed 74.2 mg buprenorphine implant

Every claim carries the 11-digit NDC of the exact product dispensed, written in 5-4-2 format

Practices inside an opioid treatment program bundle rarely bill J0572 separately, since the weekly payment already covers the drug

HCPCS code J0572 covers oral buprenorphine/naloxone products holding 3 mg or less buprenorphine per unit. Suboxone 2 mg film, Zubsolv 1.4 mg tablet, and their generics all sit at this tier. One fact decides the claim. The code comes from total milligrams of buprenorphine, not from the brand printed on the box.

Billers who read the product name instead of the strength land on the wrong rung of the J0570-J0575 ladder. The payer then underpays or denies.

What follows is the dose-to-code mapping, plus the coverage rules that decide whether J0572 is billable at all. After that come the checks that keep a claim from bouncing.

What J0572 covers, and what it doesn’t

J0572 is a Level II J-code for oral buprenorphine/naloxone combination products at 3 mg or less buprenorphine per unit. The J section of the HCPCS Level II codes covers drugs a practice supplies rather than a pharmacy.

The Centers for Medicare and Medicaid Services maintains that code set and republishes it quarterly.

The descriptor says “oral” because it covers sublingual and buccal formulations that dissolve in the mouth, including films, strips, and tablets.

Patients do not swallow buprenorphine/naloxone whole. That distinction matters at the NDC step, since injectable buprenorphine products never report under J0572.

Which products fall under the 3 mg threshold

Any oral buprenorphine/naloxone product carrying 3 mg or less buprenorphine per unit maps to J0572. In practice, that means the low-strength films and tablets from the two brand families, plus the generics that match them.

Brand and generic products at 3 mg or less

One caution. NDC numbers change as manufacturers enter and leave the market, so treat no printed list as complete. Verify the current NDC-to-HCPCS mapping in your MAC’s crosswalk file or a maintained tool such as the AAPC code lookup before you bill. A product above 3 mg per unit belongs to J0573, J0574, or J0575 instead.

Medicare pays for J0572, but only in some settings

Medicare Part B covers J0572 when a clinician supplies the drug in an outpatient setting and bills for it directly. Coverage rarely turns on the drug itself. It turns on where the encounter happened and how that setting gets paid, so start there.

The OTP weekly bundle already includes the drug

Opioid treatment programs certified by SAMHSA and enrolled in Medicare bill a weekly bundle instead of individual services. That bundle, built on the G2067 series, pays for medication, counseling, and toxicology across the week.

Adding a separate J0572 line on top duplicates the drug payment, and reviewers look for exactly that pattern. Read your MAC’s local coverage article and the CMS guidance on OTP billing before you bill J0572 inside a program.

Office-based treatment is where the code fits

Office-based opioid treatment, or OBOT, is the setting this code was built for. The Consolidated Appropriations Act of 2023 removed the DEA X-waiver, so any DEA-registered practitioner can now treat opioid use disorder without extra certification. That change widened who can prescribe, not what can be billed.

Prescribing and administering still part company at the claim. The clinician has to supply and give the dose in the office for J0572 to apply. If the patient carries the medication home, a pharmacy claim replaces the J-code entirely.

Medicaid rules stop at the state line

Most state Medicaid programs cover buprenorphine/naloxone for opioid use disorder. Past that point, the details diverge. Prior authorization, quantity limits, and preferred drug list placement all vary by state, and states revise them regularly.

California, for one, reinstated a controlled substance policy for buprenorphine products in 2023. Check the current formulary for the state you bill, then confirm the requirement with the plan before the visit.

The fee schedule resets every January

Medicare’s allowed amount for J0572 comes from the Physician Fee Schedule, and CMS republishes it each January. No printed dollar figure survives that cycle, so none appears here.

Look the code up in the CMS fee schedule search for your MAC locality, and repeat that at the start of every year.

Facility and non-facility rates are not interchangeable

Two rates exist for the same code. The non-facility rate applies in a physician office and runs higher, because it absorbs the practice’s own overhead. The facility rate applies in a hospital outpatient department or an ambulatory surgical center.

There, the facility bills its own overhead through OPPS or the ASC payment system. Clinicians who see patients in both settings are the ones who mix these up.

Place of service decides which rate applies

POS 11 on a hospital encounter creates a facility mismatch, and the payer usually trims the payment rather than denying the line. Those adjustments slip past a team that reconciles on the deposit alone.

Read the remittance instead, and scan adjustment codes against J0572 lines once a month. A pattern shows up there long before an audit finds it.

A missing NDC is the fastest route to a denial

CMS requires the National Drug Code on every outpatient drug claim, and a missing or malformed NDC rejects the line automatically. Use the 11-digit 5-4-2 format, taken from the package the patient actually received.

On a professional claim, CMS-1500 or 837P, the NDC rides in the drug identification field. On an institutional claim, it sits in the revenue code loop instead.

Documentation behind a clean claim then has to establish three facts:

• The diagnosis, usually F11.20 or another opioid use disorder ICD-10 code
• The product given, with its strength, quantity, and route
• The clinical reason the encounter happened at all

Six errors that send this claim back

• Incorrect unit count: One unit of J0572 covers a dose of up to 3 mg buprenorphine. Two units apply only when the patient genuinely receives two separate 3 mg doses. A single 6 mg dose is one unit of J0573.
• Missing NDC: Include the 11-digit NDC in 5-4-2 format, meaning labeler, product, then package. Most payers reject the line without it.
• Wrong rung on the ladder: Read the strength, not the brand. Suboxone film comes in four strengths and three of them are not J0572.
• OTP bundling conflict: A separate J0572 line alongside a weekly bundle claim reads as a duplicate. Settle which pathway applies before anyone submits.
• Wrong place of service: POS 11 on a hospital outpatient encounter creates a rate mismatch and cuts the payment down.
• No Medicaid prior authorization: Many state plans require PA for buprenorphine/naloxone. Build that check into intake rather than into billing.

Run this check before you submit

Five questions, half a minute, before the claim leaves the queue:

• Does the NDC match the package the patient received, rather than a generic equivalent?
• Is the total buprenorphine dispensed inside the band for the code you picked?
• Have you counted units as doses, rather than milligrams divided by three?
• Does the place of service match where the encounter happened?
• Is an active prior authorization on file, where the payer asks for one?

Buy-and-bill, from purchase order to paid claim

Buy-and-bill means the practice buys the drug, gives it to the patient, and bills the payer for the product. Oral buprenorphine sees far less of this than infused drugs do. It still happens in office-based treatment, usually when a clinician observes a first dose to confirm the patient tolerates it.

1. Acquire the drug: Buy from a licensed wholesaler and keep the purchase invoices, because auditors ask for them. Buprenorphine is DEA Schedule III, so storage follows DEA rules for controlled substances.
2. Verify the NDC: Record the 11-digit NDC off the packaging before administration. The claim must carry the NDC of that product, never a generic equivalent.
3. Administer and document: Note the product, strength, quantity, route, and date in the patient record. Add the prescribing clinician and the clinical indication alongside it.
4. Pick the code, then bill one unit: Add up the total milligrams of buprenorphine dispensed, then match that total to its tier code. Bill a single unit of the code you land on. Dividing milligrams by three and rounding up gives the wrong answer above 6 mg.
5. Submit the claim: Report the code with its unit count, the NDC, the ICD-10 diagnosis, and the correct POS. Keep the encounter summary on file for audit support.

42 CFR Part 2 changes how SUD billing data travels

Opioid use disorder claims rarely travel alone. E/M codes, psychotherapy codes, and toxicology codes often share the same date of service. SAMHSA expects treatment programs to pair medication with counseling and monitoring, so the services stack up on one day.

One rule sets this work apart from general medical billing. 42 CFR Part 2 protects substance use disorder treatment records more tightly than HIPAA does. Sharing them with another provider needs the patient’s explicit consent, not a routine treatment disclosure.

Billing data attached to a J0572 claim can itself fall under Part 2, depending on the context. Have counsel review how your billing and record-sharing procedures handle it. A system that keeps SUD records separate from general health records makes the rule far easier to honor day to day.

Pick the right rung on the J0570-J0575 ladder

Four codes describe the same combination drug at different doses. One covers buprenorphine on its own. The last one is not even an oral product. The thresholds sit close together, which is why selection in this family turns up so often in opioid use disorder audits. The ladder below shows where each dose lands.

Three doses, three different codes

Start from the milligrams and read across. Three encounters make the pattern obvious.

• A patient takes one Suboxone 2 mg/0.5 mg film. Total buprenorphine is 2 mg, so the claim carries one unit of J0572.
• The same patient takes two of those films. Total buprenorphine is 4 mg, which crosses into the next band, so the claim carries one unit of J0573.
• A third patient takes one Suboxone 8 mg/2 mg film. Total buprenorphine is 8 mg, so the claim carries one unit of J0574.

Billers who recognize the brand and stop reading are the ones who file 4 mg and 8 mg doses as J0572. A short lookup sheet, mapping every strength you stock to its code, closes that off. Review the sheet each quarter, since generic strengths reach the market on their own schedule.

How Pabau keeps J0572 claims moving

Most billing teams work a J0572 claim across two screens. The encounter note sits in one system and the claim form in another, so the NDC and the unit count get retyped somewhere in between. Every retype is a chance to transpose a digit or grab last month’s package.

Pabau is practice management software that keeps the record and the claim in one place. Its claims management software pre-fills the CMS-1500 straight from the encounter.

The code attached to the service lands on the charge line, and the diagnosis comes from the client’s recorded problem list. Built-in ICD-10-CM and CPT/HCPCS lookup libraries let a biller confirm a descriptor without leaving the claim.

Before the send button unlocks, Pabau checks that the claim’s required fields are complete. On US claims it also runs real-time eligibility, posts ERA remittances back against the original charge, and tracks claim status.

Your team then spends its time on the doses that need a judgment call. Nobody chases a membership number that never reached the form.

Stop retyping the same claim twice

Pabau pre-fills the CMS-1500 from the encounter record and checks that required claim fields are complete. It also posts ERA remittances back against the original charge, so your billers work one screen instead of three.

Book a demo

Conclusion

Three decisions carry a J0572 claim. Match the total milligrams to the right rung of the ladder. Attach the NDC of the product the patient actually received. Then confirm that no OTP bundle already pays for the drug. Miss one and the claim comes back.

None of that is difficult once. It gets difficult at volume, across a team, on codes that sit 3 mg apart. So write the dose-to-code sheet, run the pre-submission check, and let your system carry the steps that never needed a person.

Book a demo to see how Pabau moves an opioid use disorder claim from the encounter note to the remittance.

Continue your research

Need the reason code behind a rejection? Denial codes in medical billing lists the remittance adjustment codes that hit drug claims most often.

Working denials one at a time? Denial management in healthcare covers the workflow from remittance code to resubmission.

Not sure how to read a remittance? Electronic remittance advice explains what each adjustment line says about the payment.

Building the encounter record behind the claim? What a superbill includes shows the fields that support a drug charge under audit.

New to the revenue cycle? Medical billing explained walks through the full path from encounter to payment.

Frequently asked questions